KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Work In Process (2019 - 2025)

Ionis Pharmaceuticals (IONS) has disclosed Work In Process for 7 consecutive years, with $8.7 million as the latest value for Q1 2025.

  • For Q1 2025, Work In Process rose 44.84% year-over-year to $8.7 million; the TTM value through Mar 2025 reached $8.7 million, up 44.84%, while the annual FY2024 figure was $6.7 million, 21.95% up from the prior year.
  • Work In Process hit $8.7 million in Q1 2025 for Ionis Pharmaceuticals, up from $6.7 million in the prior quarter.
  • Across five years, Work In Process topped out at $8.7 million in Q1 2025 and bottomed at $954000.0 in Q2 2021.
  • Average Work In Process over 5 years is $4.4 million, with a median of $3.9 million recorded in 2022.
  • Year-over-year, Work In Process plummeted 72.52% in 2021 and then surged 311.64% in 2022.
  • Ionis Pharmaceuticals' Work In Process stood at $5.8 million in 2021, then plummeted by 63.45% to $2.1 million in 2022, then surged by 159.7% to $5.5 million in 2023, then rose by 21.95% to $6.7 million in 2024, then soared by 30.92% to $8.7 million in 2025.
  • According to Business Quant data, Work In Process over the past three periods came in at $8.7 million, $6.7 million, and $6.7 million for Q1 2025, Q4 2024, and Q3 2024 respectively.